Article Sidebar
Published:
Aug 22, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Clinical efficacy of idebenone in stroke patients with mild cognitive impairment, and its effect on regional homogeneity of resting-state functional magnetic resonance imaging of the brain
Abstract
Purpose: To evaluate the clinical efficacy of Idebenone in stroke patients with mild cognitive impairment, and its effect on regional homogeneity (ReHo) of resting-state functional magnetic resonance imaging (rs-fMRI) of the brain.
Methods: One hundred and twenty stroke patients with mild cognitive impairment who were admitted to the Department of Neurology of the China Rehabilitation Research Center Beijing Boai Hospital from January 2018 to January 2020 were enrolled in this study. The patients were randomly divided into control group and study group. Control group was treated with nimodipine, while the study group received a combination of nimodipine and idebenone.
Results: Clinical efficacy was higher in the study group than in the control group (p < 0.05). Scores on Montreal cognitive assessment (MoCA), mini-mental state examination (MMSE), and activity of daily living scale (ADL) were significantly elevated (p < 0.05) in both groups after treatment, but scores for MoCA and ADL were significantly higher in the study group than in the control group (p < 0.05). After 6 months of treatment, there were significantly more patients with improved clinical dementia rating (CDR)in the study group than in the control group (p < 0.05).
Conclusion: The use of idebenone and nimodipine for treatment of stroke patients with cognitive dysfunction leads to significant improvement in clinical outcomes, and enhancement of cognitive function and quality of life, due to improved brain function in the precuneus. However, the mechanism involved in the combination therapy-induced enhancement of cognitive function requires further investigation.
Keywords: Stroke; Cognitive dysfunction; Resting-state functional magnetic resonance imaging of brain; Regional homogeneity; Quality of life
